{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-067485","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.360562+00:00","generated_at":"2026-06-01T06:45:44.987253+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Iovance reports $363M cash, 50+ ATCs onboard for Amtagvi; frontline melanoma data shows 65.2% ORR","bullets":["Cash position of ~$363M as of 3/31/2024; 600+ employees and 50+ payers covering 200M+ lives have approved Amtagvi for at least one patient.","50 Authorized Treatment Centers onboarded by 5/28/2024; targeting ~70 by end of 2024; 100+ patients enrolled by 5/9/2024.","EU submission for Amtagvi planned in 2Q2024; UK and Canada submissions in 2H2024.","Phase 2 frontline melanoma (IOV-COM-202 Cohort 1A) results: ORR 65.2%, CR 30.4%, median PFS not reached at 21.7 months follow-up.","Registrational TILVANCE-301 Phase 3 trial for frontline melanoma randomized first patient in 2Q2023; dual primary endpoints ORR and PFS."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-067485","json":"https://secwatch.observer/filing/0001104659-24-067485.json","markdown":"https://secwatch.observer/filing/0001104659-24-067485.md","text":"https://secwatch.observer/filing/0001104659-24-067485.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924067485/0001104659-24-067485-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924067485/tm2416237d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:45:44.987253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}